

JUL. 7. 2004 3:33PM

AVENTIS US PAT DEPT

NO. 5029 P. 1

RECEIVED
CENTRAL FAX CENTER

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE

JUL 07 2004

Applicants Docket Number:
GI0010 US CNT1

Applicants:
SLLJKHUIS, et al.

Serial No.
10/084,814

Filing Date:
February 2, 2002

Title of Invention:
PROCESS FOR OXIDATION OF STEROIDS AND GENETICALLY ENGINEERED CELLS USED
THEREIN

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, Patent Application, at 703-872-9306, on
Date of Deposit July 7, 2004
Printed Name of Person Signing Certificate Jonas Pierre, Sr.
Signature

Total Number of Pages Sent: 4

Attorney: F. Aaron Dubberley
Reg. No. 41,001
Group Art Unit: 1652

Examiner: STEADMAN, David J.

OFFICIAL

TO: Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input checked="" type="checkbox"/> Revocation of Power of Attorney with New
Power of Attorney and Change of
Correspondence Address; Statement Under
37 CFR 3.73(b) | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____ |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telexopy transmission are intended only for the use of the individual or entity named above. If you have received this
telexopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
SLIJKHUIS, et al.

Application No.: **10/084,814**

Filed: **February 2, 2002**

Title: **PROCESS FOR OXIDATION OF
STEROIDS AND GENETICALLY
ENGINEERED CELLS USED
THEREIN**

Examiner: **STEADMAN, David**

Art Unit: **1652**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, 00

July 7, 2004

Date of transmission

Signature

J. Aaron Dubberley, Sr.

SUBMISSION OF REVOCATION OF POWER OF ATTORNEY WITH
NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONSE
ADDRESS AND STATEMENT UNDER 37 CFR 3.73(b)

Mail Stop Patent Application
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sirs:

Attached herewith, please find the Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address and the Statement Under 37 CFR 3.73(b) for the present application.

The Commissioner is hereby authorized to charge any fees incurred by this paper to Deposit Account No. 18-1982. The Commissioner is also authorized to credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

F. Aaron Dubberley, Reg. No. 41,001
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, NJ 08807-0800
 Telephone (908) 231-3737
 Telefax (908) 231-2626

Aventis Docket No. GI0010 US CNT1

JUL. 7, 2004 3:33PM

AVENTIS US PAT DEPT

NO. 5029 P. 3

RECEIVED
CENTRAL FAX CENTER

JUL 07 2004

OFFICIAL

PTO/SB/02 (08-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	10/084,814
Filing Date	February 2, 2002
First Named Inventor	SLIJKHUIS, et al.
Art Unit	1652
Examiner Name	STEADMAN, David J.
Attorney Docket Number	GI0010 US CNT1

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners associated with the Customer Number:

005487

Please change the correspondence address for the above-identified application to:

The address associated with
Customer Number:

005487

OR

Firm or
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Name Philippe-Pierre Bouvet

Signature 

Date June 1, 2004

Telephone 33.1.5571.7692

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/96 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Aventis Pharma S. A.Application No./Patent No.: 10/084,814 Filed/Issue Date: February 2, 2002Entitled: PROCESS FOR OXIDATION OF STEROIDS AND GENETICALLY ENGINEERED CELLS USED THEREINAventis Pharma S. A. , a French Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. An assignment from the Inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 5567, Frame 634, or for which a copy thereof is attached.

OR

B. A chain of title from the Inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 1, 2004

Date

33.1.5571.7692

Telephone number

Philippe-Pierre Bouvet

Typed or printed name

Signature

Aventis Pharma S.A.

Fondé de Pouvoir

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-3199 and select option 2.